Literature DB >> 31430699

In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in Mycobacterium abscessus.

Ivy B Ramis1, Júlia S Vianna2, Lande Silva Junior3, Andrea von Groll1, Daniela F Ramos1, Marcio Marçal Lobo4, Nilo Zanatta4, Miguel Viveiros5, Pedro E Almeida da Silva1.   

Abstract

Herein, we evaluated tetrahydropyridine (THP) compounds (NUNM) as antimicrobials and inhibitors of the efflux mechanism in M. abscessus. subsp. abscessus. The modulation factor (MF) of efflux inhibitors was calculated from the minimum inhibitory concentrations (MICs) of amikacin (AMI), ciprofloxacin (CIP) and clarithromycin (CLA) in the absence and presence of subinhibitory concentrations of the NUNM compounds and canonical inhibitors carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and verapamil (VP). The kinetics of the intracellular accumulation of the fluorimetric substrate ethidium bromide (EtBr) was evaluated and calculated by the relative final fluorescence (RFF). In addition, molecular modeling simulations for the MmpL5 and Tap efflux transporters with ligands (CLA, NUNM, CCCP, VP and EtBr) were performed to better understand the efflux mechanism. We highlight the NUNM01 compound because it reduced the MICs of AMI, CIP and CLA by 4-, 4- and 16-fold, respectively, had the highest effect on EtBr accumulation (RFF = 3.1) and showed a significant in silico affinity for the evaluated proteins in docking simulations. Based on the analyses performed in vitro and in silico, we propose that NUNM01 is a potential pharmacophore candidate for the development of a therapeutic adjuvant for M. abscessus infections.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; Molecular modeling; Mycobacteria; Tetrahydropyridine; efflux

Mesh:

Substances:

Year:  2019        PMID: 31430699     DOI: 10.1016/j.tube.2019.07.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

Review 1.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

2.  Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical, Mycobacterium abscessus Isolates.

Authors:  Qi Guo; Jianhui Chen; Shaoyan Zhang; Yuzhen Zou; Yongjie Zhang; Dongdong Huang; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Infect Drug Resist       Date:  2020-02-12       Impact factor: 4.003

Review 3.  Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models.

Authors:  Saloni Saxena; Herman P Spaink; Gabriel Forn-Cuní
Journal:  Biology (Basel)       Date:  2021-01-29

4.  Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) Exhibits Direct Antibacterial Activity Against Mycobacterium abscessus.

Authors:  Suting Chen; Tianlu Teng; Zhuman Zhang; Yuanyuan Shang; Hua Xiao; Guanglu Jiang; Fen Wang; Junnan Jia; Lingling Dong; Liping Zhao; Naihui Chu; Hairong Huang
Journal:  Infect Drug Resist       Date:  2021-03-23       Impact factor: 4.003

Review 5.  Efflux Pump Inhibitors Against Nontuberculous Mycobacteria.

Authors:  Laura Rindi
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

6.  The Contribution of Efflux Pumps in Mycobacterium abscessus Complex Resistance to Clarithromycin.

Authors:  Júlia S Vianna; Diana Machado; Ivy B Ramis; Fábia P Silva; Dienefer V Bierhals; Michael Andrés Abril; Andrea von Groll; Daniela F Ramos; Maria Cristina S Lourenço; Miguel Viveiros; Pedro E Almeida da Silva
Journal:  Antibiotics (Basel)       Date:  2019-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.